Bionomics ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neuphoria Therapeutics Inc (NEUP)
Neuphoria Therapeutics Inc stock price live, this page displays NASDAQ NEUP stock exchange data. View the NEUP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neuphoria Therapeutics Inc real time stock price chart below.
What Is the Neuphoria Therapeutics Inc Stock Price Today?
The Neuphoria Therapeutics Inc stock price today is 4.3700.
What Is the Stock Symbol for Neuphoria Therapeutics Inc?
The stock symbol for Neuphoria Therapeutics Inc is "NEUP."
What Stock Exchange Does Neuphoria Therapeutics Inc Trade On?
Neuphoria Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neuphoria Therapeutics Inc a Good Stock to Buy?
Determining whether Neuphoria Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEUP quote. (ISIN: US64136E1029)
What Is the Neuphoria Therapeutics Inc Stock Price Today?
The Neuphoria Therapeutics Inc stock price today is 4.3700.
What Is the Stock Symbol for Neuphoria Therapeutics Inc?
The stock symbol for Neuphoria Therapeutics Inc is "NEUP."
What Stock Exchange Does Neuphoria Therapeutics Inc Trade On?
Neuphoria Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Neuphoria Therapeutics Inc a Good Stock to Buy?
Determining whether Neuphoria Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEUP quote. (ISIN: US64136E1029)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.2101
4.4900
52 wk Range
3.6450
21.4004
NEUP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.21014.4900
52 wk Range
3.645021.4004
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NEUP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
0.0000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
- Form 13G Neuphoria Therapeutics Inc. For: 6 February
- Investing.com
- Bionomics ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13G Neuphoria Therapeutics Inc. For: 6 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.0000
Earnings
Latest Release
May 15, 2026
EPS / Forecast
-0.09 / -0.42
Revenue / Forecast
-- / --
Compare NEUP to Peers and Sector
Metrics to compare | NEUP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEUPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −2.4x | −0.5x | |
PEG Ratio | 0.01 | −0.10 | 0.00 | |
Price/Book | 0.8x | 2.5x | 2.6x | |
Price / LTM Sales | −1,780.2x | 6.5x | 3.0x | |
Upside (Analyst Target) | 60.2% | 175.3% | 58.6% | |
Fair Value Upside | Unlock | 3.5% | 10.2% | Unlock |
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Neuphoria Therapeutics (NEUP) Stock Price Today?
The Neuphoria Therapeutics stock price today is 4.3700 USD.
What Stock Exchange Does Neuphoria Therapeutics Trade On?
Neuphoria Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Neuphoria Therapeutics?
The stock symbol for Neuphoria Therapeutics is "NEUP."
What Is the Neuphoria Therapeutics Market Cap?
As of today, Neuphoria Therapeutics market cap is 23.6200M USD.
What Is Neuphoria Therapeutics's Earnings Per Share (TTM)?
The Neuphoria Therapeutics EPS (TTM) is -4.9531.
From a Technical Analysis Perspective, Is NEUP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Neuphoria Therapeutics Stock Split?
Neuphoria Therapeutics has split 0 times.
How Many Employees Does Neuphoria Therapeutics Have?
Neuphoria Therapeutics has 8 employees.
What is the current trading status of Neuphoria Therapeutics (NEUP)?
As of Jun 15, 2026, Neuphoria Therapeutics (NEUP) is trading at a price of 4.3700 USD, with a previous close of 4.3700 USD. The stock has fluctuated within a day range of 4.2101 USD to 4.4900 USD, while its 52-week range spans from 3.6450 USD to 21.4004 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.